Iterum Therapeutics (ITRM) Stock Price, News & Analysis

Company Overview

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI). Iterum’s development strategy seeks to leverage the broad spectrum of activity exhibited by sulopenem against resistant Gram-negative pathogens, with the goal of offering a seamless transition from hospital to outpatient care via its oral formulation.

Incorporated in 2014 and headquartered in Dublin, Ireland, Iterum Therapeutics maintains additional operations in the United States, including a presence in Malvern, Pennsylvania, to support clinical and regulatory activities. The company is backed by a management team and board with extensive experience in anti-infective drug discovery, clinical development and life-cycle management. Iterum continues to advance its pipeline through ongoing regulatory interactions and clinical studies aimed at meeting unmet medical needs in infectious diseases.

Key Stats

• Today's Range: $0.64 to $0.73
• 50-Day Range: $0.63 to $1.13
• 52-Week Range: $0.61 to $3.02
• Volume: 1.24 million shs
• Average Volume: 687,689 shs
• Market Capitalization: $32.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Iterum Therapeutics Stock Analysis - MarketRank™

Iterum Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 448th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Iterum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Iterum Therapeutics has a consensus price target of $9.00, representing about 1,218.7% upside from its current price of $0.68.

Amount of Analyst Coverage

Iterum Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Iterum Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Iterum Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.79% of the float of Iterum Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Iterum Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Iterum Therapeutics has recently decreased by 22.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Iterum Therapeutics does not currently pay a dividend.

Dividend Growth

Iterum Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.79% of the float of Iterum Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Iterum Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Iterum Therapeutics has recently decreased by 22.29%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.45

News Sentiment

Iterum Therapeutics has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Iterum Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for ITRM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Iterum Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Iterum Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,800.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.40% of the stock of Iterum Therapeutics is held by insiders.

Percentage Held by Institutions

Only 9.21% of the stock of Iterum Therapeutics is held by institutions.

ITRM Stock Analysis - Frequently Asked Questions

How have ITRM shares performed this year?

Iterum Therapeutics' stock was trading at $1.77 at the start of the year. Since then, ITRM shares have decreased by 61.4% and is now trading at $0.6825.

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics PLC (NASDAQ:ITRM) announced its earnings results on Tuesday, August, 5th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.03.
Read the conference call transcript.

When did Iterum Therapeutics' stock split?

Iterum Therapeutics's stock reverse split on the morning of Thursday, August 18th 2022.The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Iterum Therapeutics IPO?

Iterum Therapeutics (ITRM) raised $80 million in an initial public offering on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Who are Iterum Therapeutics' major shareholders?

Iterum Therapeutics' top institutional investors include Jane Street Group LLC (0.21%). Insiders that own company stock include Michael W Dunne, Corey N Fishman, Brenton Karl Ahrens and Sailaja Puttagunta.
View institutional ownership trends.

How do I buy shares of Iterum Therapeutics?

Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Iterum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Iterum Therapeutics investors own include NVIDIA (NVDA), Onconova Therapeutics (ONTX), Zoom Communications (ZM), Tesla (TSLA), Meta Platforms (META), SNDL (SNDL) and Atossa Genetics (ATOS).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 9/14/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ITRM
• CIK: 1659323
• Web: www.iterumtx.com
• Phone: (531) 669-4820
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Iterum Therapeutics: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +1,218.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -65.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.69
• Quick Ratio: 2.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.15) per share
• Price / Book: -4.55

Miscellaneous

• Outstanding Shares: 47,169,000
• Free Float: 46,037,000
• Market Cap: $32.19 million
• Optionable: Not Optionable
• Beta: 3.04